Journal of Global Oncology

The Journal of Global Oncology (JGO) is an exclusively online, open access publication dedicated to addressing cancer care and research, particularly in areas with limited healthcare resources. JGO seeks to be a valuable platform for sharing high-quality research that highlights the various challenges faced by healthcare professionals in resource-limited environments. The journal publishes a range of article types, including original research reports, review articles, commentaries, correspondence, special articles, and editorials.

National

English

Journal

Outlet metrics

Domain Authority

Ranking

Global

#66210

United States

#28857

Health/Health

#678

Traffic sources

Monthly visitors

Articles

The Evolution of the ASCO Educational Book and the Issues Shaping the Future of Oncology

1 week ago | ascopubs.org | Nate Pennell |Don S. Dizon

On the inaugural episode of ASCO Education: By the Book, Dr. Nathan Pennell and Dr. Don Dizon share reflections on the evolution of the ASCO Educational Book, its global reach, and the role of its new companion podcast to further shine a spotlight on the issues shaping the future of modern oncology. TRANSCRIPTDr. Nathan Pennell:Hello, I'm Dr. Nate Pennell, welcoming you to the first episode of our new podcast,ASCO Education: By the Book.
Tamales: Celebrating a Mexican Christmas Tradition

2 weeks ago | ascopubs.org | Mikkael A. Sekeres |Megan M. Dupuis

Narrator: Tamales, by Megan Dupuis, MD, PhDI do not know if you know this, but tamales are an important—nay, critical—part of the MexicanChristmas tradition. Before I moved to Texas, I certainly did not know that. I did not know that the simple tamal, made of masa flour and fillings and steamed in a corn husk, is as essential to the holiday season as music and lights. Whole think pieces have been written in The Atlantic about it, for God’s sake. But, I did not know that.
Host Transition: Meet Cancer Stories New Host Dr. Mikkael Sekeres

Jan 14, 2025 | ascopubs.org | Lidia Schapira |Mikkael A. Sekeres

Dr. Lidia Schapira: Hello and welcome to JCO's Cancer Stories: The Art of Oncology, which features essays and personal reflections from authors exploring their experience in the field of oncology. I'm your host, Dr. Lidia Schapira, a Professor of Medicine at Stanford University, and with me today is Dr. Mikkael Sekeres, who is a Professor of Medicine and the Chief of the Division of Hematology at the Sylvester Comprehensive Cancer Center in Miami.
Analysis of 20 Independently Performed Assays to Measure Homologous Recombination Deficiency (HRD) in Ovarian Cancer: Findings From the Friends' HRD Harmonization Project | JCO Oncology Advances

Nov 4, 2024 | ascopubs.org | Hillary Andrews |Lisa M. McShane |Elise C. Kohn

1-3 Patients with high-grade serous ovarian cancer (HGSOC) whose tumors are HRD have better outcomes when treated with PARPi maintenance therapy.4-7 Nearly half of patients with HGSOC have HRD, and approximately half of patients with HRD or about 20% of all patients with HGSOC have a deleterious or potentially deleterious mutation in BRCA1 or BRCA2 (BRCA1/2),7-10 which are integral to the homologous recombination repair (HRR) pathway.
Sexual Health and Quality of Life in Patients With Low-Risk Early-Stage Cervical Cancer: Results From GCIG/CCTG CX.5/SHAPE Trial Comparing Simple Versus Radical Hysterectomy

Oct 1, 2024 | ascopubs.org | Sarah Ferguson |Lori Brotto |Janice Kwon

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center
Circulating Tumor DNA Sequencing for Biologic Classification and Individualized Risk Stratification in Patients With Hodgkin Lymphoma

Sep 30, 2024 | ascopubs.org | Julia Mattlener |Sophia Sobesky |Janine Altmüller

Authors retain all rights in any data supplements associated with their articlesThe ideas and opinions expressed in these Data Supplements do not necessarily reflect those of the American Society of Clinical Oncology (ASCO). The mention of any product, service, or therapy in these Data Supplements should not be construed as an endorsement of the products mentioned.
JCO Oncology Advances

Sep 12, 2024 | ascopubs.org | Pamela L. Kunz

A world where cancer is prevented or curedFounded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. Through research, education, and promotion of the highest-quality, equitable patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy.
Implementation of a Novel Pathway to Integrate Palliative and Oncology Care for Patients With Acute Myeloid Leukemia in a Community Hospital

Sep 9, 2024 | ascopubs.org | Jason Webb |Thomas W. LeBlanc |Thomas Leblanc |Michael A. Horst

Historically, patients with hematologic malignancies are referred to palliative care less often and later in the disease trajectory than those with solid tumors. Recent evidence demonstrates the benefit of early, integrated inpatient palliative care (PC) for patients with acute myeloid leukemia (AML) receiving chemotherapy at academic centers.
Cancer Survivors' Experience of Care and Financial Toxicity: Results From a National Survey

Aug 22, 2024 | ascopubs.org | Michael Halpern |Carla Thamm |Raymond Chan

Financial toxicity (FT) can adversely affect quality of life, treatment adherence, and clinical outcomes. Patient experience of care (PEC) captures patient's perspectives on interactions with health care providers (HCPs) and systems, but the impact of PEC on FT is unknown. This study examined the relationship between PEC and FT. We used data from the 2016-2017 Medical Expenditure Panel Survey (MEPS) Experience with Cancer Survivorship Supplement.
Current and Novel Treatment Options in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer | JCO Oncology Practice

Aug 21, 2024 | ascopubs.org | Erin Roesch

Metastatic breast cancer (mBC) remains an incurable disease, and most patients will experience disease progression during their treatment course. Although endocrine therapy remains the mainstay of treatment for hormone receptor–positive/human epidermal growth factor receptor 2–negative mBC, significant progress has been and continues to be made in the treatment of this BC subtype.